George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Likely some news tomorrow
Playcards - You thinking of selling?
3/4 of 2022 profits wiped out - ?
Bank of Ireland fined €750k for data breaches - that was a deadly fine can see a pull back again under 9euros
In 8.37euros today out 9.07euros soon
Starting to move back up - credit suisse was a bad bank when Bank of Ireland’s Francesca McDonagh appointed COO of Credit Suisse good its away now
Very well done calling 8.50euros - AIB 3.29euros i see next week - BIRG 9.03 it will hold at that
Close my AIB buy @ 3.73 - was only in for a punt - Got a hunch something not right about AIB will pull the price down monday!
Nice 1 got it - moving up now - little over 9 i will sell it 500euros for the weekend
Its beats me why its 8.51 - in for 8.49 thats it if i get it
Our #CEO is attending next weeks #BIOEuropeSpring event by
@EBDgroup
in Basel.
We look forward to meeting industry colleagues & discussing #POLB's exciting portfolio of products & platforms - march -20th-22th
Poolbeg also partnered with AI-led company OneThree Biotech in February of 2022 to identify new drug targets and treatments for Respiratory Syncytial Virus. Working together, the collaboration aims to build a tailored AI analysis model, using human challenge trial data to identify disease-relevant cell signalling pathways which could lead to novel drug targets. In December 2022, Poolbeg announced that the collaboration had identified a number of promising drug candidates. Again, Poolbeg notes that the analysis will prioritise drugs with existing Phase I safety data, majorly reducing time and costs.
Both partnerships are industry firsts, with the OneThree Biotech partnership marking the first time AI analysis has been undertaken on RSV human challenge trial data and equally, the collaboration with CytoReason marking the first time AI has been used to analyse influenza human challenge trial data. In this sense, Poolbeg is yards beyond its competitors and demonstrates how AI can be incredibly beneficial in speeding up the otherwise timely and costly drug discovery process.
Huld!!!!! - Maybe top up now 0.46 we will likely double soon
Top up time
Looking more positive now - we will have a great H1 2023 shoot it back over 11euros
Our X CEO will sort it out - There was always problems with credit swissie not a irish problem - our banks are in great shape - come on back over 9euros - AIB back over 3.50
AIB 3.39 bought 10k
Hopefully back over 9euros today - happy with that
Big mistake john hume and IR This is the bottom now very certain another 1k 8.57
1k 8.47euros